Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.

@article{Gelibter2003ClinicallyMR,
  title={Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.},
  author={Alain Jonathan Gelibter and Anna Ceribelli and Michele Milella and Marcella Mottolese and Amina Vocaturo and Francesco Cognetti},
  journal={Journal of experimental & clinical cancer research : CR},
  year={2003},
  volume={22 3},
  pages={
          481-5
        }
}
Preclinical research and ongoing clinical trials are validating epidermal growth factor receptor (EGFR) as a suitable molecular target in cancer therapy. Here we report the case of a 39-year-old non-smoking man with heavily pretreated stage IV bronchioloalveolar NSCLC who was treated with gefitinib ('Iressa', ZD1839) at the dose of 250 mg/day, orally. Symptomatic relief was already detectable after 2 weeks of gefitinib therapy, pulmonary function tests readily improved, performance status went… CONTINUE READING